EMEA-001813-PIP01-15

Key facts

Active substance
Recombinant humanized anti-MMP9 monoclonal antibody IgG4 (GS-5745)
Therapeutic area
Gastroentology-Hepatology
Decision number
P/0146/2016
PIP number
EMEA-001813-PIP01-15
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
  • Treatment of Crohn's disease
  • Treatment of ulcerative colitis
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Gilead Sciences International Ltd

Tel. +44 (0)1223 897300
E-mail: regulatory.pip@gilead.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating